Clinical TrialJun 8, 2026, 07:00 AM
Tango Therapeutics Vopimetostat Combo Data Positive; Plans Phase 3 for PDAC
AI Summary
Tango Therapeutics announced positive initial data from its Phase 1/2 study of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors for MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). The vopimetostat plus daraxonrasib combination showed a 90% 6-month progression-free survival (PFS) rate and a 92% objective response rate (ORR) in PDAC patients, with both combinations being generally well-tolerated. These compelling results support the company's plan to rapidly advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer.
Key Highlights
- Vopimetostat plus daraxonrasib combo showed 90% 6-month PFS rate in PDAC patients.
- Vopimetostat plus daraxonrasib combo achieved 92% objective response rate (ORR) in PDAC (11/12 patients).
- Vopimetostat plus daraxonrasib combo demonstrated 100% disease control rate (DCR) in PDAC.
- Both vopimetostat combinations were generally well-tolerated with no new safety signals observed.
- Tango Therapeutics plans to rapidly advance vopimetostat plus daraxonrasib into Phase 3 development for first-line MTAP-deleted pancreatic cancer.
- Vopimetostat plus zoldonrasib combo showed 52% ORR and 74% 6-month PFS rate in PDAC.
- Company anticipates finalizing Phase 3 design in 2H 2026 and disclosing lung cancer monotherapy data in 2H 2026.
Price Impact
More from TNGX